J. Bérille
About
J. Bérille is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, J. Bérille has authored 48 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in J. Bérille's work include Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (21 papers) and Cancer Treatment and Pharmacology (13 papers). J. Bérille is often cited by papers focused on Lung Cancer Treatments and Mutations (33 papers), Lung Cancer Research Studies (21 papers) and Cancer Treatment and Pharmacology (13 papers). J. Bérille collaborates with scholars based in France, United States and Australia. J. Bérille's co-authors include K. Mattson, Rodryg Ramlau, Janet Dancey, Frances A. Shepherd, Mark Allen O’Rourke, Susan Coughlin, Yong Kim, Nathan Levitan, Ronald L. Burkes and Richard J. Gralla and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and European Journal of Cancer.
In The Last Decade
J. Bérille
48 papers receiving 2.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| J. Bérille France | 16 | 2.4k | 2.3k | 484 | 283 | 242 | 48 | 3.1k | ||
| Vera Gorbounova Russia | 13 | 2.2k 0.9× | 1.8k 0.8× | 617 1.3× | 354 1.3× | 280 1.2× | 23 | 3.2k | ||
| Sofia Paul United States | 11 | 1.8k 0.7× | 1.9k 0.8× | 464 1.0× | 244 0.9× | 140 0.6× | 24 | 2.7k | ||
| Tetsu Shinkai Japan | 29 | 2.0k 0.8× | 1.8k 0.8× | 782 1.6× | 184 0.7× | 401 1.7× | 146 | 3.2k | ||
| G. Frasci Italy | 22 | 1.3k 0.5× | 976 0.4× | 400 0.8× | 315 1.1× | 178 0.7× | 97 | 1.9k | ||
| J. Blatter Germany | 21 | 1.3k 0.5× | 1.8k 0.8× | 516 1.1× | 338 1.2× | 345 1.4× | 66 | 2.7k | ||
| R. Delva France | 21 | 1.3k 0.5× | 1.3k 0.6× | 657 1.4× | 538 1.9× | 395 1.6× | 99 | 2.5k | ||
| Christian Rothermundt Switzerland | 25 | 1.0k 0.4× | 971 0.4× | 755 1.6× | 371 1.3× | 265 1.1× | 79 | 2.3k | ||
| Coleman K. Obasaju United States | 32 | 2.3k 0.9× | 3.0k 1.3× | 775 1.6× | 427 1.5× | 600 2.5× | 157 | 4.1k | ||
| B. Massidda Italy | 23 | 1.6k 0.7× | 848 0.4× | 302 0.6× | 662 2.3× | 292 1.2× | 84 | 2.3k |
Countries citing papers authored by J. Bérille
Since
Specialization
Citations
This map shows the geographic impact of J. Bérille's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Bérille with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Bérille more than expected).
Fields of papers citing papers by J. Bérille
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by J. Bérille. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Bérille. The network helps show where J. Bérille may publish in the future.
Co-authorship network of co-authors of J. Bérille
This figure shows the co-authorship network connecting the top 25 collaborators of J. Bérille. A scholar is included among the top collaborators of J. Bérille based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Bérille. J. Bérille is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Morice, Philippe, Philippe Rouanet, Annie Rey, et al.. (2012). Results of the GYNECO 02 Study, an FNCLCC Phase III Trial Comparing Hysterectomy with No Hysterectomy in Patients with a (Clinical and Radiological) Complete Response After Chemoradiation Therapy for Stage IB2 or II Cervical Cancer. The Oncologist. 17(1). 64–71.
2.
Rezaï, Keyvan, Saı̈k Urien, Nicolás Isambert, et al.. (2011). Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients. Cancer Chemotherapy and Pharmacology. 68(6). 1529–1536.
3.
Obéric, Lucie, F. Viret, Charlotte Baey, et al.. (2011). Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival. Radiation Oncology. 6(1). 124–124.
4.
Penel, Nicolas, Charles Fournier, & J. Bérille. (2010). Proposal for size justification of expanded cohort at phase-2-recommended dose. Investigational New Drugs. 29(4). 713–715.
5.
Bruno, René, Robert Olivares, J. Bérille, et al.. (2003). Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.. PubMed. 9(3). 1077–82.
6.
Shepherd, Frances A., Janet Dancey, Rodryg Ramlau, et al.. (2000). Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy. Journal of Clinical Oncology. 18(10). 2095–2103.
7.
Mattson, K., Johan Vansteenkiste, Roger Stupp, et al.. (2000). Phase II study of docetaxel alternating with cisplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer. Anti-Cancer Drugs. 11(1). 7–13.
8.
Mattson, K., Lionel Bosquée, G Dabouis, et al.. (2000). Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice. Lung Cancer. 29(3). 205–216.
9.
Belani, Chandra P., Joachim von Pawel, A Płużańska, et al.. (2000). A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 29(1). 60–60.
10.
Roszkowski, Kazimierz, A Płużańska, Maciej Krzakowski, et al.. (2000). A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 27(3). 145–157.
11.
Bennouna, Jaafar, Alain Monnier, Alain Rivière, et al.. (2000). A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer. European Journal of Cancer. 36(9). 1107–1112.
12.
Latreille, Jean, Karen A. Gelmon, Vera Hirsh, et al.. (1998). Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Investigational New Drugs. 16(3). 265–270.
13.
Cesne, Axel Le, G G Chabot, J. Bérille, et al.. (1995). Phase I–II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer. Lung Cancer. 13(1). 69–78.
14.
Riviére, A., Axel Le Cesne, J. Bérille, Silvia M. Baio, & Thierry Le Chevalier. (1994). Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: Preliminary report of a French multicentre phase II trial. European Journal of Cancer. 30(5). 587–590.
15.
Rudd, R.M., et al.. (1994). Phase II study of fotemustine in untreated inoperable non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 34(5). 444–446.
16.
Pujol, Jean-Louis, Alain Monnier, J. Bérille, et al.. (1994). Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. British Journal of Cancer. 69(6). 1136–1140.
17.
Khayat, David, B. Giroux, J. Bérille, et al.. (1994). Fotemustine in the Treatment of Brain Primary Tumors and Metastases. Cancer Investigation. 12(4). 414–420.
18.
Berthaud, P., Thierry Le Chevalier, J. Bérille, et al.. (1989). Phase II study of pirarubicin in advanced non-small cell lung cancer. European Journal of Cancer and Clinical Oncology. 25(9). 1337–1338.
19.
Chevalier, Thierry Le, S. Gouva, E. Quoix, et al.. (1989). Phase II multicentre study of the nitrosourea fotemustine in inoperable squamous cell lung carcinoma. European Journal of Cancer and Clinical Oncology. 25(11). 1651–1652.
20.
Berthaud, P., Thierry Le Chevalier, J. Bérille, et al.. (1989). Phase II study of pirarubicin in advanced non-small cell lung cancer. European Journal of Cancer and Clinical Oncology. 25(10). 1507–1508.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Vera Gorbounova Breakdown of academic impact, for papers by Sofia Paul Breakdown of academic impact, for papers by Tetsu Shinkai Breakdown of academic impact, for papers by G. Frasci Breakdown of academic impact, for papers by J. Blatter Breakdown of academic impact, for papers by R. Delva Breakdown of academic impact, for papers by Christian Rothermundt Breakdown of academic impact, for papers by Coleman K. Obasaju Breakdown of academic impact, for papers by B. Massidda